The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries involving bypass did not result in significant benefits at preventing death ...
Patients who receive a heart valve replacement are well-known to be at a high risk for stroke, blood clots and deep vein thrombosis, especially during the weeks immediately after surgery. Current ...